TRIMOVAX (MMR) ATTENUATED LIVE VIRUS VACCINE AGAINST MEASLES MUMPS AND RUBELLA

Indications

• Hypoalbuminemia
• Volume resuscitation in shock
• Liver cirrhosis
• Nephrotic syndrome
• Burns
• Postoperative fluid management

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations based on clinical condition and patient response.

Adults: Refer to the appropriate guidelines for specific dosing recommendations based on clinical condition and patient response.

Mechanism of action

Albumin acts by maintaining oncotic pressure in the vascular system, thus preventing fluid from leaking into tissues and promoting the return of interstitial fluid to the bloodstream. This action helps restore blood volume and improve circulation in patients with conditions that lead to hypovolemia or edema. Additionally, albumin can bind and transport various endogenous and exogenous substances, influencing their distribution and elimination.

Pharmacodynamics

The primary pharmacodynamic effect of albumin is the increase in plasma oncotic pressure, which helps to retain fluid within the vascular space. This effect is critical in managing conditions associated with fluid imbalance. Albumin also has antioxidant properties and may play a role in modulating inflammatory responses, although these effects are secondary to its role in volume expansion.

Pharmacokinetics

Albumin is administered intravenously, where it is distributed rapidly throughout the vascular compartment. The half-life of albumin in circulation is typically around 15 to 20 days, depending on physiological conditions. It is metabolized primarily in the liver, with a small percentage undergoing renal clearance. The distribution volume is influenced by factors such as hydration status and the presence of diseases affecting protein levels.

Contra-indications

• Severe anemia
• Congestive heart failure
• Pulmonary edema
• Severe dehydration
• Allergy to albumin or any component of the formulation

Adverse effects

• Allergic reactions including anaphylaxis
• Headache
• Nausea
• Vomiting
• Fever
• Hypotension
• Fluid overload

Interactions

• Caution should be exercised when administering with other fluids or medications that may affect fluid balance
• May alter the pharmacokinetics of certain drugs due to changes in plasma volume

Precautions

• Monitor for signs of fluid overload, especially in patients with heart or kidney disease
• Use cautiously in patients with a history of allergic reactions
• Ensure proper storage and handling to avoid contamination

Pregnancy

Albumin is generally considered safe during pregnancy when administered for appropriate indications, but its use should be assessed on a case-by-case basis.

Breast-feeding

Albumin can be used during breastfeeding, as it is a naturally occurring protein in human milk.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light and use within the expiry date.

Formulations

• Human albumin solution (various concentrations)
• Albumin (500 mL bags, 20% and 5% solutions)

Indications

• Measles
• Mumps
• Rubella
• Yellow fever
• Varicella (chickenpox)
• Rotavirus

Dosage

Children: Refer to specific vaccine guidelines for paediatric dosing.

Adults: Refer to specific vaccine guidelines for adult dosing.

Mechanism of action

Attenuated vaccines work by mimicking a natural infection. The weakened pathogen replicates in the body, stimulating the immune system to produce a response against it, which includes the activation of T-cells and the production of antibodies. This prepares the immune system to recognize and fight off the pathogen if exposed in the future.

Pharmacodynamics

The pharmacodynamics of attenuated vaccines involve the interaction of the attenuated pathogen with the host's immune system. Upon administration, the vaccine induces both humoral (antibody-mediated) and cell-mediated immunity. This leads to the development of memory cells that ensure a faster and more effective response upon subsequent exposure to the actual pathogen.

Pharmacokinetics

Attenuated vaccines are generally administered via subcutaneous or intramuscular injection. The pharmacokinetics are characterized by the distribution of the vaccine components within the body, with the attenuated organisms replicating locally and inducing an immune response. The onset of immunity typically occurs within weeks, and the duration of immunity can vary depending on the specific vaccine.

Contra-indications

• Severe immunodeficiency
• Pregnant women (specific live attenuated vaccines)
• Severe allergic reactions to vaccine components

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Low-grade fever
• Malaise
• Rash
• Rare neurological complications (e.g., Guillain-Barré syndrome)

Interactions

• Immunosuppressive agents (may reduce vaccine efficacy)
• Blood products (may interfere with immune response to vaccine)
• Other live vaccines (timing may affect immune response)

Precautions

• History of allergic reactions to previous vaccinations
• Presence of active infections
• Chronic illnesses that may affect immune response

Pregnancy

Live attenuated vaccines are generally contraindicated during pregnancy due to potential risks to the fetus.

Breast-feeding

Most live attenuated vaccines are considered safe during breastfeeding, but caution and consultation with a healthcare provider are advised.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Injectable suspension
• Oral suspension
• Lyophilized powder for reconstitution

Dosage

Children: Dosage for human-derived biological products in pediatrics should be determined based on specific product guidelines and the clinical context.

Adults: Dosage for human-derived biological products varies widely. Refer to specific product information for appropriate dosing.

Mechanism of action

Human physiology is governed by complex biological systems involving various cellular and molecular pathways. The mechanisms of action for human-derived biological products vary widely depending on the specific context, including immune response, hormonal regulation, and metabolic processes.

Pharmacodynamics

Pharmacodynamics in humans involves the interaction of drugs with biological systems, resulting in therapeutic effects. This includes receptor binding, signal transduction, and physiological responses. The effects are influenced by genetic factors, existing health conditions, and concurrent medications.

Pharmacokinetics

Pharmacokinetics in humans involves the absorption, distribution, metabolism, and excretion (ADME) of substances. Factors such as age, sex, body weight, and organ function can significantly influence these processes. Drug absorption may occur via oral, intravenous, or other routes, while distribution depends on blood flow and tissue permeability. Metabolism typically occurs in the liver, and excretion primarily takes place through the kidneys.

Pregnancy

There is no specific information available; consult local guidelines.

Breast-feeding

There is no specific information available; consult local guidelines.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Measles
• Mumps
• Rubella
• Varicella (chickenpox)
• Yellow fever
• Rotavirus
• Intranasal influenza

Dosage

Children: Refer to the BNF for Children for specific dosing information based on age and vaccine type.

Adults: Refer to specific product guidelines for dosing information, as it can vary by vaccine type and brand.

Mechanism of action

Live vaccines work by introducing a weakened or attenuated form of a pathogen into the body. This stimulates the immune system to recognize and respond to the pathogen, leading to the production of antibodies and memory cells that provide long-term protection against future infections by the same pathogen.

Pharmacodynamics

The pharmacodynamics of live vaccines involve the activation of both humoral and cellular immunity. Following vaccination, the immune system generates a robust response, including the production of specific antibodies and the activation of T cells that can recognize and eliminate infected cells. This dual action helps establish long-term immunity.

Pharmacokinetics

The pharmacokinetics of live vaccines vary depending on the specific vaccine. Generally, the vaccine is administered via injection, allowing the live attenuated organisms to enter the bloodstream. The immune response typically begins within days and can last for years, depending on the vaccine. Live vaccines are usually stored under refrigeration to maintain their viability, and they should be administered within their expiration dates.

Interactions

• livevaccines + abrocitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + baricitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + filgotinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + dexrazoxane: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + iron chelators: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + ozanimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + ponesimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + siponimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + upadacitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + diroximelfumarate: Moderate (increases risk of generalised infection (possibly life-threatening))

Indications

• Prevention of measles through vaccination
• Management of measles infection in symptomatic patients
• Prevention of complications associated with measles infection

Dosage

Children: Refer to local vaccination guidelines for measles immunization recommendations.

Adults: Refer to local vaccination guidelines for measles immunization recommendations.

Mechanism of action

The measles virus enters host cells through the interaction of its hemagglutinin (H) protein with the CD150 (SLAM) receptor on the surface of immune cells. Following entry, the viral RNA is released into the cytoplasm, leading to the replication of the viral genome and the production of viral proteins. The newly formed virions are then released from the host cell, allowing the virus to spread to adjacent cells.

Pharmacodynamics

Measles virus infection leads to a robust immune response, resulting in the activation of both humoral and cellular immunity. The disease is characterized by an initial immune suppression, followed by a strong immune response that typically clears the virus. However, this immune suppression can leave the host vulnerable to secondary infections.

Pharmacokinetics

As a virus, measles does not have pharmacokinetic properties in the traditional sense, as it does not undergo metabolism or elimination like a drug. Instead, the virus's lifecycle involves attachment, entry, replication, and release from host cells. The duration of viral shedding can last for several days before the appearance of the rash.

Contra-indications

• Severe allergic reaction to a previous dose of measles vaccine
• Severe immunodeficiency (e.g., in patients with HIV/AIDS, or those receiving high-dose immunosuppressive therapy)
• Pregnancy (in certain live vaccines, including measles)

Adverse effects

• Fever
• Rash
• Diarrhea
• Otitis media
• Pneumonia
• Encephalitis (rare)

Interactions

• Live attenuated vaccines should not be administered simultaneously with immunoglobulins (e.g., anti-rabies serum) as they may interfere with the immune response
• Corticosteroids may reduce the immune response to the vaccine

Precautions

• Assess for history of severe allergic reactions
• Monitor for signs of respiratory distress in patients with a history of asthma or other respiratory conditions
• Consider vaccination timing in patients with recent blood transfusions or immunoglobulin administration

Pregnancy

Measles vaccination is contraindicated during pregnancy due to potential harm to the fetus. Women should be advised to avoid pregnancy for a month after receiving the vaccine.

Breast-feeding

Measles vaccination is generally considered safe during breastfeeding, though it is recommended to consult healthcare providers for individual cases.

Storage

Store in a refrigerator at 2°C to 8°C, do not freeze. Protect from light.

Formulations

• Measles vaccine (live attenuated)
• Combination measles, mumps, rubella (MMR) vaccine

Indications

• Prevention of mumps through vaccination
• Management of mumps infection
• Monitoring for complications such as orchitis or meningitis

Dosage

Children: Refer to the BNF for Children for specific vaccination schedules and dosage recommendations related to the MMR vaccine.

Adults: Refer to the specific guidelines for vaccination, typically the MMR vaccine is administered as a two-dose series, with the first dose given at 1 year of age and a second dose at 4 to 6 years of age. Further details should be checked in the relevant vaccination schedule.

Mechanism of action

The mumps virus enters host cells by binding to sialic acid receptors on the surface of the cells. Once inside, the virus releases its RNA genome, leading to the production of viral proteins and replication of the viral genome. The newly formed viral particles are then released from the host cell, allowing for further infection of adjacent cells.

Pharmacodynamics

Mumps primarily affects the salivary glands but can also impact other organs such as the testes, ovaries, pancreas, and central nervous system. The immune response to the infection typically involves the activation of T cells and the production of antibodies, which help to clear the virus from the body. The severity of the disease can vary, with some individuals experiencing mild symptoms while others may develop complications such as orchitis or meningitis.

Pharmacokinetics

The pharmacokinetics of the mumps virus is not applicable in the traditional sense as it is a viral infection. However, the incubation period for mumps is typically 16 to 18 days, with the virus being contagious from approximately three days before to five days after the onset of parotitis. The immune response develops over a period of weeks, leading to long-lasting immunity in most cases post-infection or vaccination.

Adverse effects

• Fever
• Headache
• Muscle pain
• Swelling of the salivary glands
• Orchitis (inflammation of the testes)
• Oophoritis (inflammation of the ovaries)
• Meningitis
• Encephalitis

Precautions

• Individuals with weakened immune systems should be monitored closely.
• Vaccination may be less effective in those with specific conditions affecting the immune response.

Pregnancy

Mumps vaccination is generally avoided during pregnancy unless the benefits outweigh the risks, as the effects of the vaccine on fetal development are not fully established.

Breast-feeding

Vaccination is not contraindicated during breastfeeding, but consultation with a healthcare provider is recommended.

Storage

Store at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.

Formulations

• Live attenuated mumps virus vaccine

Indications

• Monitoring fetal health
• Assessing placental function
• Diagnosis of placental insufficiency
• Management of pregnancy-related complications

Dosage

Children: Dosing is not applicable as the placenta is not a pharmacological agent but a biological organ.

Adults: Dosing is not applicable as the placenta is not a pharmacological agent but a biological organ.

Mechanism of action

The placenta acts as a barrier and interface between maternal and fetal blood, allowing for nutrient and gas exchange while preventing direct contact of maternal and fetal blood. It produces hormones such as human chorionic gonadotropin (hCG), progesterone, and estrogen, which support pregnancy and fetal growth. Additionally, the placenta plays a role in immune tolerance, protecting the fetus from maternal immune responses.

Pharmacodynamics

The placenta's pharmacodynamics involve the regulation of various hormones and factors that influence maternal metabolism, immune response, and blood flow. It modulates the maternal body's adaptation to pregnancy, ensuring adequate blood supply and nutrient delivery to the developing fetus. The placenta also influences the transfer of certain medications and substances between mother and fetus, impacting fetal development.

Pharmacokinetics

The pharmacokinetics of substances transferred through the placenta depend on their molecular weight, lipid solubility, and binding properties. Small, lipophilic molecules can cross the placenta easily, while larger or more polar molecules may have restricted transfer. The placenta also has enzymatic activity that can metabolize certain drugs, affecting their bioavailability and potential fetal exposure.

Pregnancy

Placental tissue is integral to pregnancy and is not contraindicated. However, any interventions involving placental tissue should be approached with caution and under medical supervision.

Breast-feeding

The use of placental tissue in any form has not been extensively studied in breastfeeding, and caution is advised.

Storage

Placental tissue should be stored at controlled room temperature and protected from light. Specific storage requirements may vary based on the formulation and processing.

Indications

• Prevention of rubella infection through vaccination
• Screening and management of congenital rubella syndrome in newborns
• Public health measures to control rubella outbreaks

Dosage

Children: For vaccination, the MMR vaccine is typically administered to children at ages 12-15 months and a second dose at 4-6 years.

Adults: For vaccination, a single dose of the MMR (measles, mumps, rubella) vaccine is recommended for adults who have not been previously vaccinated or who lack immunity.

Mechanism of action

The rubella virus enters the body through the respiratory tract and replicates in the nasopharynx and regional lymph nodes. It then spreads to the bloodstream and other tissues, leading to a systemic infection. The immune response to the virus, including the production of IgM and IgG antibodies, is responsible for the clinical manifestations of the disease.

Pharmacodynamics

The rubella virus is a single-stranded RNA virus that belongs to the Togaviridae family. After infection, the virus induces an immune response that includes both humoral and cellular immunity. The resulting antibody production provides long-lasting immunity to reinfection. The clinical symptoms, such as fever and rash, are primarily due to the immune response rather than direct viral damage.

Pharmacokinetics

The incubation period for rubella is typically 14 to 21 days. The virus is present in the nasopharynx and urine. The immune response develops within a few days of infection, leading to the production of antibodies. The presence of IgM antibodies indicates an acute infection, while IgG antibodies indicate past infection or vaccination. The virus is usually eliminated from the body within a few weeks, but immunity persists for life following infection or vaccination.

Contra-indications

• Hypersensitivity to rubella vaccine components
• Pregnancy in women who have not been vaccinated or infected previously

Adverse effects

• Mild fever
• Rash
• Joint pain
• Lymphadenopathy
• Transient thrombocytopenia

Interactions

• Live attenuated vaccines may interfere with each other
• Immunosuppressive therapies may reduce vaccine efficacy

Precautions

• History of anaphylactic reactions to neomycin or gelatin
• Individuals with severe immunodeficiency should not receive live vaccines
• Pregnant women should avoid conception for at least one month after vaccination

Pregnancy

Rubella vaccination is contraindicated during pregnancy due to potential harm to the fetus. Women are advised to receive the vaccine before conception.

Breast-feeding

Rubella vaccination is considered safe during breastfeeding.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Live attenuated rubella vaccine

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.